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Abstract
Background: Pregnancy is associated with improvement in immunoregulation that persists into
the geriatric phase. Impaired immunoregulation is implicated in Alzheimer’s disease (AD)
pathogenesis. Hence, we investigate the relationship between pregnancy and AD.
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Methods: Cross-sectional cohort of British women (N = 95). Cox proportional hazards modeling
assessed the putative effects of cumulative months pregnant on AD risk and the mutually adjusted
effects of counts of first and third trimesters on AD risk.
Results: Cumulative number of months pregnant, was associated with lower AD risk (β = −1.90,
exp(β) = 0.15, P = .02). Cumulative number of first trimesters was associated with lower AD risk
after adjusting for third tri-mesters (β = −3.83, exp(β) = 0.02, P < .01), while the latter predictor
had no significant effect after adjusting for the former.
Conclusions: Our observation that first trimesters (but not third trimesters) conferred protection
against AD is more consistent with immunologic effects, which are driven by early gestation, than
estrogenic exposures, which are greatest in late gestation. Results may justify future studies with
immune biomarkers.
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Introduction
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Inflammatory processes are implicated in the pathogenesis of Alzheimer’s disease (AD).1,2
Reproductive life history is known to influence inflammatory pathways and affect
inflammatory disease activity, both in terms of short-term symptomology (eg, asthma,3
rheumatoid arthritis,4,5 multiple sclerosis6) and long-term risk (eg, allergies,7,8 systemic
sclerosis,9,10 rheumatoid arthritis4,11,12). Pregnancy is an especially important modifier of
women’s inflammatory activity. Inflammation as a possible link warrants an investigation of
whether a woman’s pregnancy history influences her AD risk. Only a small number of
studies have addressed the possibility that aspects of reproductive life history might
influence AD risk, and authors largely ignore inflammation in discussing those results. We
critically evaluate these studies and further discuss how reproductive life history affects risk
of other maladies with similar etiologies. Using data collected from our cross-sectional study
of British women, we explore the possibility that women’s pregnancy life history influences
risk of Alzheimer’s-type dementia.
Alzheimer’s and Adaptive Immunity

Author Manuscript

There is abundant evidence to support the concept that AD is a systemic inflammatory
disease.13,14 A full review of inflammation in AD is beyond the scope of this article, but
given the ways in which pregnancy modifies the adaptive immune system, it is important to
highlight the role of T-cells in AD etiology. T-cells are more numerous in the AD brain than
healthy brains,15,16 potentially as a result of the blood– brain barrier dysregulation that is
typical of AD neuropathy.17 Participants with AD exhibit more activated T-cells both in the
periphery and the brain compared to age-matched controls.18 This increase in T-cells has
been attributed to the CD4+ compartment,14,19 with greater concentrations of effector
memory cells (CD45RA−CCR7−), specifically late differentiated cells (CD28−CD27−), and
lower concentrations of early differentiated (CD28+CD27+) and naive CD4+ cells (CD45RA
−CCR7+).20,21

Author Manuscript

Characterization of the upregulated CD4+ cells in AD reveals that among individuals with
AD, excessive inflammation is exhibited that is type 1 dominant, with elevated levels of
TH1-associated cytokines.2,22–24 TH1 cells can influence AD pathogenesis both from within
the brain and from the periphery: Pro-inflammatory cytokines secreted by activated TH1
cells in the periphery can cross the blood–brain barrier and activate dendritic cells,
microglia, and astrocytes, and amyloid-b has an activating effect on microglia and
astrocytes, stimulating preferential TH1 proliferation.16 Importantly, while individuals with
AD exhibit proliferation of effector CD4+ cells, this is not the case for the CD4+ cells with a
suppressive phenotype, regulatory T-cells (TRegs; CD25+FoxP3+CD127low).21 In healthy
individuals, sufficient TReg supply regulates effector T-cell activity and prevents excessive
inflammation. It has been suggested that insufficient TReg repositories may contribute to AD
pathogenesis.20,21
Converging evidence suggests that alterations in CD4+ subset concentrations may be an
early hallmark of AD, potentially contributing to the pathological cascade.25,26 Upregulation
of late differentiated T-cells and depletion of naive T-cells and TRegs are apparent during the
preclinical (mild cognitive impairment [MCI]) and early stages of AD symptomology19 and
Am J Alzheimers Dis Other Demen. Author manuscript; available in PMC 2019 April 01.
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do not appear to change over the course of AD progression.21 Rodent models of AD support
the notion that the immunological changes characteristic of AD occur before neurocognitive
deterioration,26 and experimental amplification of TReg response delays onset27 and can
even reverse AD-like cognitive impairment.28 These AD-characteristic immune profiles
described here do not occur in individuals with other dementias,19,29 supporting the
likelihood that this inflammatory profile is specific to AD. Individuals with AD do not
exhibit greater degrees of immunosenescence than age-matched controls,30 suggesting that
neurotypical “inflammaging” is not responsible for these changes. Inflammaging is a
concept developed by Franceschi et al31 to describe typical, age-related, chronic, low-grade
inflammation characterized by immunosenescence, but patients with AD do not exhibit
higher concentrations of pro-inflammatory biomarkers C-reactive protein and interleukin 6
compared to controls.30

Author Manuscript

Pregnancy and Adaptive Immunity

Author Manuscript

In a woman’s (postnatal) life span, the most dramatic increases in TRegs occur during the
first trimester of pregnancy. Evidence suggests there are exponential TReg increases in preand early pregnancy, stable levels across late pregnancy, and mild increases postpartum,
which plausibly could persist for the rest of the life span. Specifically, pregnancy is
maintained by an increase in TReg cells that, some evidence suggests, could begin as early as
coitus in response to seminal fluid exposure in preparation for embryo implantation.32–36
The TReg levels rise further at implantation and during the first 2 pregnancy trimesters.32,37
Pregnancy-induced TRegs are generated in the periphery38 and migrate to the fetal–maternal
interface, leading to lower detectable levels of TRegs in the maternal periphery during
pregnancy.6 In human pregnancy (unlike murine pregnancy38), elevated TReg levels are
maintained postpartum.39,40 Somerset et al demonstrated that maternal TReg concentrations
showed a significant increase from prepregnancy to 6 to 8 weeks postpartum (4.4% vs 7.5%
of peripheral lymphocytes). The TReg levels continue to rise for a year throughout the
postpartum phase at a rate of 4% increase per month,41 and so maternal peripheral TReg
frequency is significantly higher postpartum compared with during pregnancy.6 There is
evidence that within the TReg proliferation that occurs with pregnancy, the TRegs specific for
fetal antigens are expelled with decidual tissue and those without such specificity are
retained in the maternal body.39,42,43 It remains unknown how long these changes in T-cell
subsets persist beyond 1 year postpartum.

Author Manuscript

While pregnancy induces increases in TRegs that suppress effector T-cells, there is still
immune activity during pregnancy, and immunosuppression is not complete. The effector
cells that are upregulated in pregnancy are TH2 dominant, suppressing TH1 inflammation. In
addition to the maternal immune modifications, the conceptus secretes TH2 cytokines that
downregulate TH1 cytokines,44 which may influence the maternal compartment.
In sum, the changes that occur in the CD4+ compartment during pregnancy (proliferation of
TRegs, downregulation of type 1 inflammation) are in direct contrast with the typical profile
of the CD4+ compartment in AD (depletion of TRegs, upregulation of type 1 inflammation).
We speculate that if pregnancy’s immunologic alterations persist across the life span, we
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might expect that women with more pregnancies should benefit from greater protection
against AD pathogenesis.
Hypotheses
This study tests the overarching hypothesis that women who spend more cumulative time
pregnant in their lives will experience reduction in AD risk via improvement in
immunoregulation. To test this hypothesis, our study considers women’s cumulative number
of months pregnant with relation to AD risk. If pregnancy were to protect against AD via
greater repositories of TRegs, then cumulative number of months pregnant would be a better
predictor of AD risk than parity. Cumulative number of first trimesters would be a better
predictor than parity because the major changes in TReg concentrations during pregnancy
occur in the early phase, so regardless of whether the pregnancy lasted to completion, the
benefit from increased concentrations of TRegs might persist.
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We acknowledge the possibility that even if we observe that cumulative time pregnant is
correlated with AD risk, an alternative explanation for this relationship could be related to
estrogen exposure. Cumulative months pregnant could be a proxy for duration of estrogen
exposure (via longer reproductive span) or quantity of estrogen exposure (via pregnancyassociated high concentrations of estrogen). Estrogen levels rise exponentially during
pregnancy, with typical plasma concentrations during the third trimester of pregnancy
approximately 85 times levels typical during an ovulatory menstrual cycle (calculated from
Tulchinsky and Little45). Several in vitro and animal studies have demonstrated estrogen’s
role in inhibiting and reversing AD-specific brain insults,46–50 and human studies have
investigated how lifetime duration of endogenous estrogen exposure may influence later-life
cognitive performance51–55 and AD risk.56–58 It could be hypothesized that this higher dose
of estrogen exposure might confer reduction in AD risk.
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We adopted 2 strategies for distinguishing between an immunologic versus estrogenic
explanation for pregnancy’s hypothesized effect on AD risk. Firstly, more pregnancies could
be associated with longer reproductive span, defined as the time between menarche and
menopause, which has been used as a proxy measure of duration estrogen exposure.59,60 We
addressed the possibility of cumulative time pregnant acting as a proxy for reproductive span
by adjusting for reproductive span in all analyses. Secondly, more pregnancies could be
associated with greater quantity of estrogen exposure. If pregnancy were to protect against
AD via greater concentrations of estrogen, later pregnancy would exert a more potent antiAD effect than early pregnancy because of the exponential nature of estrogen’s increase
across the course of pregnancy. We addressed the possibility of cumulative months pregnant
acting as a proxy for high doses of estrogen exposure by conducting 2 separate analyses of
the reliance of AD risk upon a woman’s cumulative number of first trimesters (proxy for
immunoregulation) and the reliance of AD risk upon a woman’s cumulative number of third
trimesters (proxy for estrogenic neuroprotection).
A summary of our hypotheses is that we anticipate (1) cumulative months pregnant will be
negatively associated with AD risk, (2) cumulative months pregnant will be a better
predictor of AD risk than parity, and (3) cumulative number of first trimesters will be a
better predictor of AD risk than cumulative number of third trimesters.
Am J Alzheimers Dis Other Demen. Author manuscript; available in PMC 2019 April 01.
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Methods
Cohort
Women aged 70 to 100 years along with family member(s) and/or carer(s) were recruited for
participation through nursing homes, churches, community centers, the Alzheimer’s Society,
and a retired employee community from 2010 to 2012. Participants received a modest gift
voucher as incentive. The protocol had approval from the University of Cambridge Human
Biology Research Ethics Committee. Participants were informed of research purpose,
activities, and confidentiality. Proband, informant (family member or carer), and, when
necessary, legally authorized representative provided written informed consent.
Procedures

Author Manuscript
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Each session consisted of an interview collecting information about reproductive history and
factors that would potentially confound the relationship of dementia status with reproductive
history, including use of contraceptive and menopause hormone therapies. Information was
collected through detailed interviews with probands, family members, carers, nursing home
staff, and written records, when necessary and available. Exclusionary criteria included self,
informant, or carer report of proband having non-Alzheimer’s-type dementia (eg, vascular,
Parkinsonian) or any possible external injury to the brain (eg, head impact injury, brain
tumor). Ten cases were excluded from the analysis because of these criteria (Table S1). A
weakness in the study design was lack of information gathered about immunopathology.
Dementia status was measured by the Clinical Dementia Rating (CDR) scale, consisting of a
60- to 90-minute interview conducted in 2 parts, one with the proband and the other with an
informant, that is, her relative or carer. In the CDR, probands are evaluated in 6 categories:
memory, orientation, judgment and problem–solving, home and hobbies, community affairs,
and personal care. The “sum of boxes (SOB)” was used as a continuous variable, as has
become standard in clinical trials,61,62 computed from the sum of each category score
creating a scale from 0 to 18. Cases and controls were not distinguished until CDR-SOB
scores were calculated, at which time individuals scoring “0” were designated as controls.
Details of the study protocol are described in previous publications.58,63
Variable Calculations

Author Manuscript

Age at Alzheimer’s onset.—For the purposes of the Cox model, the time-to-event was
defined as years between age 50 and CDRSOB score turning from 0 to 0.5, indicating onset
of AD symptoms. This was estimated based on CDR-SOB score at the time of interview.
Using published AD progression norms64 (typical number of years spent in each dementia
phase), a scale was created to estimate age at onset for each possible CDR-SOB score by
interpolating CDR-SOB scores between the end points of other scales’ categories. Year at
which CDR-SOB score would have progressed from 0 to 0.5 was back-extrapolated from the
observed degree of dementia at the time of interview. Details of this methodology are
described in Supplementary Methods.
Predictive variables.—Cumulative months pregnant was calculated in a comprehensive
manner, such that all pregnancies including miscarriages and medical terminations were
included. Information was collected about the trimester at which spontaneous and elective
Am J Alzheimers Dis Other Demen. Author manuscript; available in PMC 2019 April 01.
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abortions occurred. For calculating cumulative months pregnant, number of first trimesters
and number of third trimesters, we considered a first-trimester pregnancy termination to be
equivalent to 3 months spent pregnant, and second trimester was considered 6 months (there
were no third-trimester terminations in this cohort). All child-yielding pregnancies,
including stillbirths, were included in the variable calculation as 9 months. Parity was
calculated as each woman’s total number of delivered births, including live births and
stillbirths. Predictive variables were natural logarithm transformed to improve the symmetry
of the distributions. Quantification of covariates follows standard procedures and is
described in Table S2. When necessary, continuous covariates were transformed to improve
symmetry of distribution. All effect size coefficients were back-transformed for
interpretability (Figure 1).
Statistical Tests

Author Manuscript

In a main effects analysis, each predictive variable contributed into the Cox model a
coefficient, “coef,” whose value is estimated on the basis of the data. When exponentiated,
“exp(coef),” this parameter yields the ratio of hazards (probability of AD onset per unit
time) between 2 hypothetical women who are identical except for a unit difference between
their respective values of the predictive variable. “Alzheimer’s disease-free time” was
defined as the retrospectively estimated number of years in excess of age 50, prior to the
interview, during which the woman was free from AD. The AD-free time for those women
who were judged to be free from AD at the time of the interview was treated as right
censored, as is common practice in survival analysis. The dependency of AD-free time on
the predictive variables was analyzed via Cox proportional hazards model. Plots of the
martingale residuals revealed that the model fits were not unduly influenced by particular
cases (Figures S1 and S2).
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We undertook a 2-step process to select covariates for the Cox models. Firstly, we identified
all variables that might confound the statistical relationship between pregnancy history and
AD risk (Table S2). Each of these variables was independently tested for covariance with
each predictive and outcome variable. Secondly, those variables that exhibited significant (P
< .10) relationships with both a predictive and an outcome variable were included in models.
Additionally, 2 interaction terms were included to investigate whether subsets of women
exhibited different relationships between pregnancy history and AD risk based upon (1)
whether or not they breastfed and (2) whether or not they had a first-degree relative with
dementia. These 2 interaction terms were selected because of previously reported
importance of breastfeeding history and family history of dementia with AD risk in this
cohort.63

Author Manuscript

Additionally, for cases (CDR-SOB > 0), we performed a linear regression to check whether
incomplete pregnancies were statistically related to the degree of dementia (CDRSOB score)
at interview, in order to determine whether our ability to detect incomplete pregnancies was
biased related to proband memory impairment.
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Results
Cohort Statistics
To investigate the role of pregnancy history on AD risk in a cohort of British women, a
subset of 95 women from the total cohort of 133 women were included in the analyses. All
women were of white British ethnic identity, currently residing in England. Ten probands
from the initial cohort of 133 were excluded from analyses due to factors that would cause
non-Alzheimer’s-type dementia (eg, stroke) or could obscure the effects of reproductive
history (eg, ovarian cancer). Twenty-eight more participants were excluded due to missing
information (Table S1).

Author Manuscript
Author Manuscript

Degree of dementia at the time of interview varied across the full range of possible CDRSOB scores, with some of the participants judged to have no sign of cognitive impairment
(N = 56) and some assessed to have CDR-SOB scores of 0.5 or higher (N = 39) at interview
(Table 1). Of the controls, 83% were born in England and 86% were educated to age 16 or
less, and of the cases, 82% were born in England and 92% were educated to age 16 or less.
Comparing reproductive patterns between the control group and the case group, we observed
identical median ages at menarche, menopause, similar reproductive spans, and ages at first
birth. No statistically significant differences existed between cases and controls for any
reproductive life history variables (Table 1). We investigated potential detection bias in the
case sample and found no significant relationship between severity of dementia and number
of incomplete pregnancies in the subset of cases (linear model results: R2 = 0.0, F1,48 = 0.9,
P = .34). This null result suggests that detection of incomplete pregnancies was not biased
due to the memory loss associated with degree of dementia. Our methods involving
interview of informants and consultation of written records may have contributed to greater
accuracy than participants with dementia could have provided on their own. There were
significant differences in age at interview, education, and occupation between the case and
control subsets of the cohort (Table 1). Each of these variables was investigated for covariate
status (Table S2). Education was found to be correlated with both predictive and outcome
variables and was therefore included in multivariate models (Table S2).
Hypothesis 1: More Cumulative Months Pregnant Is Associated With Lower Alzheimer’s
Risk

Author Manuscript

In a Cox proportional hazards model adjusting for age at first birth, reproductive span, and
history of breastfeeding, marriages, and occupation, we found that AD risk had a significant
dependence on cumulative months pregnant, with more months pregnant associated with
lower AD risk (Table 2). For example, a woman who spent 3% more total months pregnant
than another (otherwise identical) woman would have approximately 5.50% (25th-75th
percentiles 3.9–7.0%) lower in AD risk (P = .02), i.e., this would apply to two (otherwise
identical) women who had spent 34 versus 33 months pregnant. Similarly, 2.8% more total
months pregnant was associated with 5.5% (25th-75th percentiles 0.5–10.3%) lower AD risk
(P = .03). These results are consistent with our prediction that pregnancy may exert longterm protective effects against AD risk potentially due to the benefits of pregnancy-induced
TReg proliferation but does not rule out other plausible biomechanisms of neuroprotection.
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In a Cox proportional hazards model controlling for age at first birth, reproductive span, and
history of breastfeeding, marriages, and occupation, we found that the number of births
(both live childbearing and stillbirths, ie, “parity”) was not significantly associated with the
risk of AD (P = .21, and P = .11 adjusted for cumulative months pregnant; Table 2). This
metric, parity, is a less precise reflection of a woman’s full pregnancy history than
cumulative months pregnant and has been the construct of interest in previous studies.
Hypothesis 3: Cumulative Number of First Trimesters Is a Better Predictor of AD Risk Than
Third Trimesters
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In separate Cox proportional hazards models, all controlling for age at first birth,
reproductive span, and history of breastfeeding, marriages, and occupation, we assessed AD
risk reliance on first trimesters alone and third trimesters alone, first while adjusting for third
trimesters and third while adjusting for first trimesters. We found that AD risk had a
significant dependence on cumulative number of first trimesters and no significant
dependence on cumulative number of third trimesters (Table 3). For example, a woman who
had 20% more first trimesters than another (otherwise identical) woman would have
approximately 30% (25th-75th percentiles 22.4–36.4%) lower AD risk (P = .02) i.e., this
would apply to two (otherwise identical) women who had 6 versus 5 total first trimesters.
Models that measure the reliance of AD risk on first trimesters while adjusting for third
trimesters, and vice versa, demonstrated similar results (Table 3). Furthermore, the 95%
confidence interval for the exponentiated coefficients do not overlap (models 6 and 8 in
Table 3), suggesting that the reduction in AD risk brought by the first 3 months of a new
pregnancy is greater than that brought by the final 3 months of an ongoing pregnancy (Table
3). These data provide evidence against the idea that greater quantity of estrogen exposure
explains pregnancy’s protective effect against AD risk, which would be most dependent on
third trimesters, and instead support the possibility of an immunoregulatory mechanism,
which would be most dependent on first trimesters.

Discussion

Author Manuscript

We find that women who spent more months of life pregnant exhibited a significant, dosedependent reduction in AD risk. Our results support the possibility that pregnancy protects
against later-life AD onset, potentially due to pregnancy’s characteristic increase in TReg
proliferation. Previous studies found effects in the opposite direction, with higher parity
associated with earlier onset of AD,55,65 and one study reported that women who had 3 or
more pregnancies had triple the AD risk.55 It is possible that the inconsistent results for the
reliance of AD risk between our study versus studies of parity could be due to those studies’
neglect of the considerable variation in breastfeeding rates and incomplete pregnancies.
Other studies have explored the relationship between women’s parity and geriatric cognitive
performance (which may or may not be indicative of AD risk) with mixed results. One study
found that higher parity was associated with better memory ability in elderly women,53 and
others have observed that estrogen replacement therapy’s beneficial effect on cognitive
function improved with increasing parity, although this effect was not statistically

Am J Alzheimers Dis Other Demen. Author manuscript; available in PMC 2019 April 01.

Fox et al.

Page 9

Author Manuscript

significant.66 However, there has been more robust evidence for the opposite trend: One
study found higher parity associated with worse cognitive function,54 and another found that
women who had 5 or more pregnancies had worse cognitive impairment compared with
those who had fewer pregnancies.51 It should be noted that pregnancy’s potential anti-AD
effect due to improvement in immunoregulation may not be relevant for non-AD-related
cognitive decline. Therefore, in these studies of non-AD cognitive decline,51,53,54,66 the
mechanisms and pathways responsible for differences in cognitive performance may be
considerably different and potentially variable between individuals and study cohorts.
Further research is necessary to resolve whether failure to consider incomplete pregnancies
and breastfeeding in studies of AD, as well as whether there may be contradictory risk
factors for AD and non-AD cognitive decline, accounts for some inconsistencies in previous
study results.

Author Manuscript

Immunoregulatory or Estrogenic Pathway?
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Our observation that more cumulative months pregnant is associated with reduced AD risk
could potentially be attributable to a number of explanations. We suggest the most likely
explanation is related to immunoregulation. Other possible explanations could be that
cumulative months pregnant is a proxy for duration of estrogen exposure (longer
reproductive span) or quantity of estrogen exposure (pregnancy-associated high
concentrations of estrogen). We address these possibilities in 2 ways. Firstly, we attended to
duration of estrogen exposure by controlling for reproductive span in all models and still
found that AD had a significant reliance on cumulative months pregnant (Table 2). Secondly,
we compared cumulative number of first trimesters (mean [M] = 3.0, standard deviation
[SD] = 1.8) to third trimesters (M = 2.5, SD 1.5). If pregnancy exerts its anti-AD effect via
recruitment of TRegs, then first trimesters would be expected to exert the stronger effect
because the most dramatic acceleration in TReg recruitment occurs from the nonpregnant to
early pregnant state.40,41 Conversely, if pregnancy exerts its anti-AD effect via quantity of
estrogen exposure, then third trimesters would be expected to exert the stronger effect
because estrogen levels rise exponentially during pregnancy. Our results are more consistent
with an immunologic explanation and less with an estrogenic mechanism.
Pregnancy and Autoimmunity

Author Manuscript

Alzheimer’s disease is characterized by a number of immuno-logic similarities with
autoimmune diseases, including not only TH1 dominance and insufficient TRegs but also the
presence of autoantibodies.67,68 There is abundant evidence that pregnancy induces
protection and relief from autoimmune diseases. Such evidence is consistent with the idea
that pregnancy induces increases in TRegs that suppress effector T-cells and mildly
upregulates TH2 inflammation. It has been known since 1938 that pregnancy is associated
with symptom relief in rheumatoid arthritis,4,5 with many people going into remission
during pregnancy.9 While previous authors have interpreted this effect with relation to
estradiol or cortisol, there has been no evidence for such an association,69,70 consistent with
the possibility that proliferation of TRegs is responsible for the suppression of inflammation
characteristic of rheumatoid arthritis.71 We posit the protective effect of TRegs in pregnancy
may have long-term advantages in protection against developing rheumatoid arthritis due to
increases in TReg cell quantity or activity that are sustained beyond pregnancy. Nulliparous
Am J Alzheimers Dis Other Demen. Author manuscript; available in PMC 2019 April 01.
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women have twice the risk of rheumatoid arthritis compared to parous women.4,11,12 In
spondyloarthropathy, another form of inflammatory arthritis, as well as autoimmune
hepatitis, pregnancy usually has beneficial effects.9,72,73 Additionally, nulliparas have
increased risk of systemic sclerosis compared with parous women,9,10 representing further
evidence for a long-term protective effect. Multiple sclerosis is a particularly relevant
disease to consider in light of AD because it is characterized by neuroinflammation. There is
significant symptom reduction during pregnancy among women with multiple sclerosis.6 A
recent study found that individuals with amnesic MCI and multiple sclerosis exhibited
similar levels of CD45+ T-cells and pro-inflammatory cytokines in cerebrospinal fluid,
suggesting similar central inflammatory profiles that manifest before AD neurocognitive
impairment.25
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There is also evidence that pregnancy induces protection and relief from atopies, which are
TH2 dominant. This evidence is consistent with the idea that pregnancy induces increases in
TRegs that suppress effector T-cells. Pregnancy may induce relief from asthma and
improvement in bronchial hyperresponsiveness.3 It is noteworthy that the improvement in
asthma symptoms was observed from preconception through the second trimester, which is
when TReg cells proliferate, and then there was no statistically significant change between
the second and third trimester. Interpretation of this trend has not previously included
discussion of TRegs but rather speculated on the role of sex steroids in asthma
symptomology.74 There is evidence that increasing parity has a beneficial effect in
diminishing maternal allergies,7,8 further evidence that pregnancy-induced change in
adaptive immunity may have long-term effects for the mother.
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Further evidence for pregnancy-induced long-term improvements in immunoregulation
comes from studies of fetal microchimerism. Fetal cells are semi-allogeneic to the mother’s
genetic identity, and after a pregnancy, fetal cells remain in the mother. It is thought that
such cells persist in the mother’s body for the duration of her lifetime,75 and thus a woman
with multiple pregnancies would carry fetal microchimeric cells of multiple genetic
identities. It has been postulated that maternal lymph nodes might contain increased levels of
TRegs in order to sustain an immunosuppressed environment to facilitate tolerance of these
populations of semiallogeneic cells,75 as has been demonstrated in fetal lymph nodes to
sustain tolerance of alloantigens.76
Research Considerations
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Limitations of this study include the small sample size, potential for recall inaccuracies or
biases which may be higher than in other cohorts due to this cohort’s age range and
dementia status, lack of biomarker data, lack of full medical history, and lack of information
on causes of miscarriage, although it would be nearly impossible to find causal information
from miscarriages that occurred as early as the 1920s. Furthermore, our data cannot test (or
rule out) the possibility that estrogenic neuroprotection requires merely a mild elevation in
estrogen concentration, and so the extremely high concentrations of third-trimester estrogen
may be irrelevantly above the necessary threshold for reduction of AD risk. We also cannot
rule out the possibility that another unknown biological pathway connects pregnancy and
AD etiology.
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The relationship between miscarriage and inflammation is unlikely to confound our model.
Firstly, we address the issue of inflammation as a cause of incomplete pregnancies in this
cohort. Sporadic miscarriage (occurring after a missed period and therefore known to the
proband) is a common and normal part of a woman’s reproductive experience, affecting an
estimated 1 in 4 pregnancy-attemptant women77 and 15% of pregnancies.78,79 There are
myriad causes of sporadic miscarriage, most often and nonexclusively chromosomal
abnormalities (observed in 75% of cases) and fetal malformation (observed in 85% of
cases),80 in addition to uterine abnormalities, cervical compromise, endocrine dysregulation,
and toxic exposure.79 In some cases, infection can cause inflammation that directly causes
miscarriage, but there is no reason to suspect that women who experience inflammationinduced miscarriage fail to benefit from the increase in TReg concentrations that occur with
seminal fluid exposure,32–35 conception, and implantation,32,37 albeit insufficient
immunosuppression to maintain the pregnancy to completion.
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Author Manuscript

Recurrent miscarriage, defined as 3 or more consecutive miscarriages, is a rarer condition
affecting an estimated 1% of pregnancy-attemptant women and can be caused by endocrine,
autoimmune, or thrombotic abnormalities,77 with the latter, sometimes, possibly caused by
cytokine degradation of vasculature.81 Because only 4% (N = 4) of the women in our cohort
experienced a total of 3 or more miscarriages (Table 1), we suspect a low rate of recurrent
miscarriage and thus a low degree to which incomplete pregnancy rates would be caused by
the immunodysfunction associated with recurrent miscarriage. Similar to the argument
above, there is no reason to suspect that women who experience inflammation-induced
miscarriage fail to benefit from the increase in TReg concentrations that characterize the
early stages of pregnancy, even if those changed are insufficient for successful gestational
maintenance. The degree to which TReg proliferation occurs and is sustained in incomplete
pregnancies is a question that requires further study. For now, there is no evidence to predict
that experiencing a miscarriage would undermine our hypothesis of long-term
immunoregulatory benefits of gestation.
Future research should expand upon our understanding of how reproductive history affects
inflammatory mechanisms in the long term. More information is especially needed on the
effects of pregnancy on T-cell activity in mothers with and without inflammatory diseases. It
will be important for studies to consider the presence of pro-inflammatory alleles in
understanding how immune system development, pregnancy, and other inflammation-related
mechanisms affect AD risk. Further research is also needed to elucidate whether each
pregnancy in a woman’s life history confers equivalent long-term changes to immune and
endocrine systems.82

Author Manuscript

Conclusion
Using data from a cohort of elderly British women, we calculated cumulative time each
woman spent pregnant and fit Cox models to test the statistical dependence of AD risk on
pregnancy history. We found that more months pregnant in the lifetime was associated with
reduced risk of AD. The more typically consulted but less comprehensive construct, parity
(number of deliveries), exhibited no significant effect. Cumulative number of first—but not
third—trimesters conferred a protective effect against AD risk. These observations are
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consistent with a protective effect of pregnancy-induced proliferation of TRegs. Reproductive
life history has an effect on maternal immune function, and there may be long-term impacts
from immune cell proliferation that occurred during a woman’s reproductive years.
Pregnancy is characterized by an immunosuppressive profile, and the increase in
concentration of regulatory immune cells may have implications for inflammatory
propensity in later life. We hope our findings prompt further study of this previously
overlooked mechanism as a possible link between women’s reproductive life history and
AD.
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Figure 1.
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Women with more cumulative months pregnant had lower AD risk. For each age, the plot
reports the covariate-adjusted probability of being AD-free for women with total lifetime
number of months pregnant below the cohort median (lower curve) and above the cohort
median (upper curve). Pointwise 95% confidence bands are also shown. The purpose of this
plot is to give a visual sense of the magnitude of the effect by dichotomizing the number of
cumulative months pregnant variable. Cox regression of the reliance of AD risk on mediansplit dichotomous characterization of cumulative months pregnant demonstrates that women
above the cohort median exhibit 37.01% lower AD risk compared with women below the
cohort median (β = −.99, exp(β) = .37, se(β) = .40, P =.01, 95% CI = 0.17–0.81). The Cox
model reported in Table 2 represents a more meaningful analysis by utilizing the continuous
cumulative months pregnant variable. AD indicates Alzheimer’s disease; CI, confidence
interval.
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Cohort Characteristics.

χ2 test P = l.0, NS
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43 (77)

10 (18)
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Alcohol consumption, n (%)

3 (5)
7(13)
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Smoking history, n (%)
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Cambridge

Place born, n (%)
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χ2 test P = l.0, NS
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b

c
χ2(8) = l7.4, P = 0.03

t(l48.l) = 3.9, P = 0.00

χ2 test P = 0.2, NS

b

t(88.5) = −5.2, P = 0.00
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3 (5)

3 (8)

P < .001,

c
P < .05.

b

While age at interview and education differed significantly between cases and controls, neither was significantly correlated with any predictors, and therefore, these potential covariates were dropped from
model design (Table S2). Occupation was included as a covariate in all models.

a

Abbreviations: CDR, Clinical Dementia Rating; NA, not applicable; NS, not significant P > .10; SD, standard deviation; SOB, sum of boxes.

>2 servings per day

Controls Versus Cases

Author Manuscript
Cases, N = 39

Author Manuscript

Controls, N = 56

Fox et al.
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Author Manuscript

Author Manuscript

Author Manuscript

Parity

Parity, adjusted for cumulative months pregnant

3

4

1.693

0.666

−2.049

−1.901

Coef

5.436

1.947

0.1289

0.1495

Exp(coef)

1.067

0.526

0.958

0.821

Se(coef)

.113 (NS)

.205 (NS)

b

.032

.021

b

P Value

0.671–44.019

0.695–5.458

0.020–0.843

0.030–0.747

95% CI

a

P < .05.

b

Cox model analysis of the dependence of AD risk on cumulative months pregnant and parity defined as number of full-term pregnancies. All models are adjusted for age at first birth, reproductive span,
and history of breastfeeding, marriages, and occupation. The table reports the partial likelihood point estimate for the effect of the parameter, the corresponding exponentiated value, the standard error, the P
value for the relative sharp null hypothesis, and the 95% confidence interval for exp(coef). The partial likelihood ratio test P value for the null hypothesis of no effect for model 1 was .005, model 2 was .
008, model 3 was .038, and model 4 was .039. The score log-rank test P value for model 1 was .004, model 2 was .007, model 3 was .055, and model 4 was .047. Models were fitted on the basis of 95
sample individuals (10 observations deleted due to ineligibility and 28 observations deleted due to lack of data), for a total of 39 observed failure events.

a

Abbreviations: CI, confidence interval; NS, not significant.

Cumulative months pregnant, adjusted for parity

Cumulative months pregnant

1

2

Parameter, Natural Log Transformed

Model Number

Cox Models Measuring Relationship Between Pregnancy History by Months and Parity and Alzheimer’s Disease Risk.

Author Manuscript

Table 2.
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Author Manuscript

Author Manuscript

Author Manuscript
a

Third trimesters

Third trimesters, adjusted for first trimesters

7

8

1.386

−8.024

−3.834

−1.936

Coef

4.000

0.448

0.022

0.144

Exp(coef)

1.358

0.703

1.292

1.807

Se(coef)

.307 (NS)

.254 (NS)

.003d

.016

c

P Value

0.280–57.226

0.113–1.777

0.002–0.272

0.030–0.702

95% CI

P < .01.

c

P < .05.

b

The table reports the partial likelihood point estimate for the effect of the parameter, the corresponding exponentiated value, the standard error, the P value for the relative sharp null hypothesis, and the 95%
confidence interval for exp(coef). The partial likelihood ratio test P value for the null hypothesis of no effect for model 5 was .058, model 6 was .002, model 7 was .122, and model 8 was .002. The score
log-rank test P value for model 5 was .023, model 6 was .001, model 7 was .061, and model 8 was .002. The models were fitted on the basis of 95 sample individuals (10 observations omitted due to
ineligibility and 28 observations omitted due to lack of data), for a total of 39 observed failure events.

Cox model analysis of the dependence of AD risk on cumulative number of first and third trimesters. All models are adjusted for age at first birth, reproductive span, and history of breastfeeding,
marriages, and occupation.

a

Abbreviations: CI, confidence interval; NS, not significant.

First trimesters, adjusted for third trimesters

First trimesters

5

6

Parameter, Natural Log Transformed

Model Number

Cox Models Measuring Relationship Between Pregnancy History by Trimester and Alzheimer’s Disease Risk.

Author Manuscript

Table 3.
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